Side Effects of IVIG in Guillain-Barré Syndrome
IVIG therapy for GBS carries several important adverse effects that require vigilant monitoring, with the most serious being thrombosis, acute renal failure, aseptic meningitis, and hypersensitivity reactions. 1
Major Serious Adverse Effects
Thrombosis
Thrombotic events represent one of the most dangerous complications of IVIG therapy, occurring even in patients without traditional risk factors 1. Risk is elevated in patients with:
- Advanced age (>65 years)
- Prolonged immobilization (common in GBS)
- Hypercoagulable conditions
- History of prior thrombosis
- Indwelling central venous catheters
- Hyperviscosity states
- Cardiovascular risk factors
Ensure adequate hydration before administration and use the minimum effective infusion rate in high-risk patients 1. Recent evidence shows that a second course of IVIG significantly increases thromboembolic events without improving clinical outcomes 2.
Acute Renal Dysfunction/Failure
Acute kidney injury, including acute tubular necrosis, proximal tubular nephropathy, and osmotic nephrosis, can occur with IVIG 1. This is particularly concerning in patients with:
- Pre-existing renal insufficiency
- Diabetes mellitus
- Age >65 years
- Volume depletion
- Sepsis
- Concurrent nephrotoxic medications
Monitor BUN and creatinine before infusion and at regular intervals; discontinue if renal function deteriorates 1. Even maltose-based IVIG formulations can cause AKI, as demonstrated in a recent case of a diabetic GBS patient who developed severe AKI requiring hemofiltration 3.
Aseptic Meningitis Syndrome (AMS)
AMS typically develops within several hours to 2 days after IVIG infusion 1, 4. Characteristic features include:
- Severe headache
- Nuchal rigidity
- Fever
- Photophobia
- Painful eye movements
- Nausea and vomiting
CSF analysis shows pleocytosis (up to several thousand cells/mm³, predominantly granulocytic), elevated protein (up to several hundred mg/dL), but negative cultures 1. Discontinuation of IVIG results in remission within several days without sequelae 1, 4.
Hypersensitivity and Anaphylaxis
Severe hypersensitivity reactions can occur even in patients who previously tolerated IVIG 1. Patients with IgA deficiency and anti-IgA antibodies are at highest risk (IVIG contains trace amounts of IgA <50 μg/mL) 1. If hypersensitivity develops, immediately discontinue the infusion and institute appropriate treatment.
Acute Encephalopathy
Rare but serious, acute encephalopathy can manifest as decreased consciousness, agitation, and diffuse brain edema on imaging 5. This typically resolves within 96 hours after IVIG withdrawal.
Metabolic and Hematologic Effects
Hyperproteinemia and Pseudohyponatremia
IVIG causes hyperproteinemia with increased serum viscosity and pseudohyponatremia 1. Critical pitfall: Distinguish true hyponatremia from pseudohyponatremia, as treating pseudohyponatremia with free water restriction leads to volume depletion, increased viscosity, and higher thrombosis risk 1.
Common Mild Adverse Effects
Headache
Headache occurs commonly (approximately 22% of patients based on comparative data) 6. Pre-treatment with corticosteroids does NOT prevent IVIG-associated headache 6.
Hepatic Dysfunction
Transient liver function abnormalities can occur, particularly when IVIG is combined with methylprednisolone (67% vs 22% with IVIG alone) 6.
Dermatologic Reactions
Dyshidrotic eczema presenting as pruritic vesicles on palms and soles can develop 3-7 days post-infusion 7. This is self-limited and responds to topical corticosteroids but may recur with subsequent IVIG courses 7.
Flu-like Symptoms
Fever, chills, myalgias, and malaise commonly occur during or shortly after infusion 3.
Critical Monitoring Strategy
Before infusion:
- Assess renal function (BUN, creatinine)
- Ensure adequate hydration
- Screen for IgA deficiency in patients with prior reactions
- Assess thrombosis risk factors
- Measure baseline blood viscosity in high-risk patients
During infusion:
- Start at 0.01 mL/kg/min (0.5 mg/kg/min)
- Monitor vital signs continuously
- Gradually increase to maximum 0.10 mL/kg/min (5 mg/kg/min) if tolerated 8
- Slow or stop if adverse reactions occur
Post-infusion:
- Monitor renal function periodically
- Watch for signs of thrombosis
- Assess for headache, meningismus, altered mental status
- Monitor for rash or other delayed reactions
Important Clinical Caveat
A second course of IVIG in non-responders increases serious adverse events (particularly thromboembolism) without improving clinical outcomes 2, 9. The 2025 SID-GBS trial definitively showed that repeat IVIG should be avoided 2. If patients fail initial IVIG, consider therapeutic plasma exchange rather than repeat IVIG 9.